Infectious Bursal Disease Virus Variants

Overview and Taxonomy of Infectious Bursal Disease Virus Variants

The infectious bursal disease virus (IBDV), the etiological agent of Gumboro disease, represents one of the most economically consequential pathogens confronting the global poultry industry. Classified within the family Birnaviridae, genus Avibirnavirus, IBDV is a non-enveloped virus possessing a bisegmented double-stranded RNA genome. The virus exhibits a marked tropism for developing B lymphocytes within the bursa of Fabricius (BF), the primary lymphoid organ in young chickens, leading to profound and often irreversible immunosuppression. The World Organisation for Animal Health (WOAH) recognizes IBD as a disease of significant socioeconomic importance, particularly in regions with intensive poultry production. The taxonomic and biological complexity of IBDV has expanded dramatically over the past four decades, driven by a relentless process of genetic mutation, reassortment, and immunological selection. This has resulted in the emergence of multiple distinct lineages, antigenic variants, and pathotypes that defy simplistic classification and challenge established control measures.

Historical Context and the Inadequacy of Early Classification Systems

For much of its early history following its initial identification in the 1960s, IBDV was considered a relatively homogeneous entity. Strains were categorized descriptively based on their pathogenic potential: the "classic" or classical virulent (cv) strains that caused clinical disease with moderate mortality, and the "very virulent" (vv) strains that emerged in Europe in the late 1980s, characterized by acute disease and high mortality rates [6, 17]. The discovery of antigenic "variant" strains in the Delmarva peninsula of the United States in the 1980s fundamentally altered this paradigm. These variants, such as the Delaware E (Del-E) and GLS strains, were notable for their ability to cause subclinical bursal atrophy in the presence of maternally derived antibodies that were protective against classic strains [19]. This revealed a critical flaw in the existing nomenclature: the term "variant" was applied to any strain exhibiting antigenic divergence from the classic or very virulent prototypes, yet these strains themselves were not antigenically homogeneous [14]. Furthermore, the advent of molecular epidemiology revealed that not all strains identified as vvIBDV by genotyping displayed the expected high pathogenicity, and that reassortment events between genome segments, whereby a segment A encoding a vvIBDV VP2 could reassort with a segment B from a different lineage, could create viruses with unpredictable biological properties [8, 17]. These complexities rendered the historical, purely descriptive nomenclature inadequate for a modern, globally connected poultry industry.

A Molecular Framework for Taxonomy: The Genogroup System

To address the taxonomic chaos, a standardized genotyping system was proposed and has been widely adopted within the scientific community. This system is predicated on the phylogenetic analysis of the hypervariable region (HVR) of the VP2 gene encoded on segment A, which corresponds to the major antigenic determinant and the primary target for neutralizing antibodies. The classification is further refined by analyzing the VP1 gene on segment B, the viral RNA-dependent RNA polymerase, which contributes to viral replication efficiency and pathogenicity [14, 30]. Under this bipartite system, isolates are designated by a genotype for segment A (e.g., A1, A2, A3) and a separate genotype for segment B (e.g., B1, B2, B3), acknowledging the potential for independent evolution and reassortment of each segment.

The major serotype 1 genotypes relevant to poultry disease include:

• Genogroup A1 (Classic): Encompasses early classical virulent strains and the majority of live attenuated vaccine strains (e.g., D78, B87, 2512) [6, 15].
• Genogroup A2 (Variant): A highly diverse group encompassing all antigenic variants, subdivided into multiple lineages. This includes the early US variants (A2a, A2b, A2c) and, critically, the emergent novel variant strains (A2d) [2, 5, 27]. A further subdivision, A2dB1b, denotes strains carrying a specific A2d segment A and a distinct B1b segment B, and has become the focus of intense global concern [29, 33, 37].
• Genogroup A3 (Very Virulent): Includes the classical very virulent strains (vvIBDV) and their reassortant derivatives (e.g., A3B1, A3B2, A3B4, A3B5) [6, 8, 16, 25].

This genogroup system has revealed an epidemiological landscape far more intricate than previously imagined, with multiple lineages coexisting, competing, and evolving under the pressure of intensive vaccination.

Molecular Basis of Antigenic Variation and Immune Escape

The taxonomic distinction between variant and non-variant strains, particularly between the novel A2d variants and the vvIBDV strains, is underpinned by specific amino acid signatures in the VP2 HVR that drive antigenic divergence. The VP2 protein is organized into several loop domains (PBC, PDE, and PFG) that form the surface-exposed projections of the viral capsid and constitute the primary binding site for neutralizing antibodies.

The novel variant strains (nVarIBDV) of genotype A2d are characterized by a constellation of key amino acid substitutions in these loops. A defining signature includes residues 252I, 254N, and 299S, which are consistently found in nVarIBDV isolates from China, Malaysia, Japan, Egypt, and other regions [2, 9, 12, 27, 28]. More profoundly, the presence of lysine at position 221 (K221) in VP2 has been identified as a unique and conserved antigenic site in nVarIBDV strains [22]. Research utilizing monoclonal antibodies has demonstrated that this K221 residue forms part of a conformational epitope that is entirely absent in classic, vv, and attenuated IBDV strains. The K221Q mutation in a nVarIBDV backbone significantly alters its reactivity profile against sera raised against vvIBDV or cIBDV, confirming its role as a critical determinant of immune escape [22]. Structural modeling suggests that K221 is surface-exposed and alters local electrostatic potential, potentially shielding other critical neutralizing epitopes from antibody recognition [22].

Further dissecting the molecular basis, experimental studies using reverse genetics have pinpointed the PDE loop (residues 249–260) as a critical "immune escape module." The combination of V252I, G254N, and I256V mutations within this loop can individually or, more potently, collaboratively reduce antigen-antibody affinity and severely interfere with serum neutralization directed against vvIBDV strains [31]. Of these, the G254N mutation was shown to exert the most significant effect on immune evasion [31]. This mechanistic understanding explains how nVarIBDV (A2d) can efficiently replicate and cause severe bursal atrophy in chickens that have been immunized with vaccines derived from classic or vvIBDV strains, a phenomenon that has been repeatedly documented in field outbreaks across China, Egypt, and Malaysia [3, 4, 26, 37]. The antigenic mismatch between the vaccine strains and the circulating nVarIBDV is so pronounced that a booster immunization with commercial vaccines cannot achieve sterile immunity or 100% protection, although it can reduce clinical signs [1, 4, 32].

The Role of Reassortment in Generating Taxonomic Diversity

The bipartite genome of IBDV provides a unique evolutionary mechanism unavailable to many other poultry viruses: segment reassortment. When a host cell is co-infected with two different IBDV strains, reassortment can produce progeny viruses with novel combinations of segment A and segment B. This process has been a major driver of taxonomic complexity and has generated lineages with altered pathogenicity and host range [8, 16].

A paradigmatic example is the emergence and global spread of the A3B1 reassortant. These viruses carry a segment A derived from a very virulent (A3) strain but a segment B derived from an US variant or classical strain (B1). Despite being genotypically vvIBDV on segment A, these reassortants often display a less virulent phenotype than the "pure" A3B2 vvIBDV strains, yet they have been able to circulate efficiently in vaccinated flocks, dominating the epidemiological landscape in Turkey and northwestern Europe in recent years [8, 16]. Conversely, the novel variant A2dB1b genotype itself is a specific reassortant combination, where a highly divergent VP2 from genogroup A2d is paired with a VP1 of the B1b lineage [29, 37]. The VP1 from the B1b lineage may confer enhanced replication efficiency or polymerase fidelity, thereby facilitating the rapid transcontinental spread of this genotype [29]. The sheer diversity of reassortment events creates a dynamic taxonomy where new "genotypes" are not merely point mutants but are chimeric viruses with potentially novel biological properties, underscoring the necessity for ongoing genomic surveillance [8, 11, 25].

Global Epidemiological Patterns and Emergence of Novel Variants

The taxonomic evolution of IBDV is inextricably linked to its global epidemiology. For over three decades following its emergence in the 1990s, the vvIBDV genotype (A3B2) was the dominant and most threatening lineage in Europe, Asia, Africa, and South America [6, 18, 20]. However, the epidemiological landscape has shifted dramatically. The most significant recent event has been the emergence and global dissemination of the novel variant IBDV (nVarIBDV), genotype A2dB1b.

First identified in China in the mid-2010s, the A2dB1b genotype rapidly became the predominant cause of subclinical, immunosuppressive IBD in vaccinated Chinese flocks, displacing vvIBDV in many regions [3, 6, 10]. From this epicenter, the virus spread with alarming speed. Molecular dating and phylodynamic analyses have traced the introduction of A2dB1b into Argentina to a single transcontinental spread event from China around 2018, after which it became established in South America [29]. Similarly, it was first detected in Egypt in 2022-2023, marking its incursion into Africa [37]. In Japan, novel antigenic variants belonging to A2d were detected from 2017 onwards and have now spread from the western to the eastern part of the country [28]. A recent molecular survey in the Near East and Persian Gulf region identified A2dB1b for the first time in Jordan, Lebanon, and the United Arab Emirates, with multiple independent introductions from Egypt, East Asia, and even South America, highlighting the complexity of its global traffic [33].

In contrast to the lethal disease caused by vvIBDV, the nVarIBDV strains establish a "silent" but damaging infection. They cause no overt clinical signs or mortality in SPF or commercial chickens, yet induce profound bursal atrophy, severe lymphocyte depletion, and prolonged immunosuppression that predisposes birds to secondary infections and reduces the efficacy of subsequent vaccinations [7, 13, 24, 26, 35, 36]. The virus exhibits a wide tissue tropism, with high viral loads detected not only in the bursa but also in the thymus, spleen, cecal tonsils, and bone marrow, a feature that likely contributes to its persistence and immunosuppressive capacity [24, 28, 34]. This subclinical pathotype has made the disease difficult to recognize, often going undetected until secondary complications or poor growth performance alert producers to its presence. The US poultry industry has not been immune to antigenic drift; recent surveillance in the Delmarva region identified an increasing prevalence of a specific amino acid signature (S215N, S317R, G322E, E323D) in circulating variant strains that significantly reduces neutralization by antibodies raised against the traditional Del-E vaccine strain, indicating a progressive antigenic drift within the US variant population [5].

Current epidemiological surveys from China (2023-2024) reveal a complex co-circulation of four distinct pathotypes: nVarIBDV (A2d, accounting for 69.9% of detections), persisting vvIBDV (A3, 16.1%), attenuated vaccine-like strains (attIBDV, 8.6%), and classical strains (cIBDV, 5.4%) [21]. Furthermore, a new class of "mutated very virulent" IBDV (mvvIBDV) has been described, representing strains that are genotypically vvIBDV (harboring markers like D279N) but phenotypically present as atypical IBD with subclinical symptoms, further blurring the lines between traditional pathotypes [21]. This perpetual emergence of new genotypes and phenotypes, driven by high mutation rates, segment reassortment, and intense vaccine-driven selection pressure, constitutes one of the most formidable challenges for the sustainable control of IBDV in the 21st century [2, 4, 6, 23].

Molecular Pathogenesis of IBDV Variants: Bursal Atrophy and Histopathological Lesions

The molecular pathogenesis of infectious bursal disease virus (IBDV) variants, particularly the recently emerged novel variant strains (nVarIBDV) belonging to genotype A2dB1, represents a paradigm shift in our understanding of how this pathogen subverts the avian immune system. Unlike the acutely lethal very virulent IBDV (vvIBDV) strains that induce rapid mortality through systemic inflammation and multi-organ failure, nVarIBDV strains orchestrate a more insidious and targeted destruction of the bursa of Fabricius (BF), the primary lymphoid organ responsible for B-cell maturation and humoral immunity in chickens. This subclinical yet profoundly immunosuppressive phenotype has rendered nVarIBDV strains a formidable challenge to global poultry production, as they disseminate silently within vaccinated flocks, inducing chronic bursal atrophy without overt clinical signs [1, 3, 10]. The World Organisation for Animal Health (WOAH) recognizes IBD as a notifiable disease of significant economic consequence, and the emergence of these variants underscores the critical need to understand the molecular determinants driving their unique pathogenicity.

Molecular Determinants of Bursal Tropism and Cellular Targeting

The foundational step in nVarIBDV pathogenesis is the highly selective tropism for actively dividing B lymphocytes within the bursal follicles. The VP2 capsid protein, particularly its hypervariable region (HVR), is the primary determinant of cell tropism and virulence. Comparative sequence analyses of nVarIBDV strains isolated across Asia, Africa, and the Americas have identified a distinct constellation of amino acid residues in the VP2 HVR that distinguish them from both classical and very virulent strains. Key signatures, including 252I, 254N, 262Y, 299S, and 318D, are consistently present in nVarIBDV isolates from China, Malaysia, Egypt, and Japan [2, 9, 27, 28]. More specifically, the presence of lysine at position 221 (K221) has been identified as a unique antigenic site exclusive to nVarIBDV strains, which is critical for immune escape from vaccine-induced antibodies [22]. This residue is surface-exposed on the VP2 projection domain, altering local electrostatic potential and facilitating evasion of neutralizing antibodies elicited by classical or vvIBDV vaccines [22].

The molecular mechanisms underlying the severe bursal atrophy observed in nVarIBDV infection are rooted in the virus's ability to productively infect and lyse IgM-bearing B cells. Sophisticated reverse genetics studies have pinpointed residues within the PDE (Phe-Tyr-Asp) loop of VP2, including V252I, G254N, and I256V, as critical mediators of immune escape and altered pathogenicity [31]. Notably, the G254N substitution was shown to be the most significant single contributor to reduced antigen-antibody affinity, a finding corroborated by in vitro neutralization assays and in vivo challenge models [31]. The cumulative effect of these mutations is a VP2 protein that retains high-affinity binding to the susceptible B-cell receptor yet simultaneously evades the humoral immune response primed by existing vaccines, a molecular tightrope that enables persistent replication within the bursa.

Histopathological Progression: From Acute Lymphoid Depletion to Chronic Fibrosis

The histopathological lesions induced by nVarIBDV are characterized by a precise and reproducible temporal sequence that begins within days of infection and culminates in irreversible architectural destruction of the bursa. At 3 days post-inoculation (dpi) , the earliest detectable changes include multifocal lymphocyte depletion within the medullary regions of bursal follicles, accompanied by the accumulation of cellular debris and pyknotic nuclei, consistent with apoptotic cell death [7, 35]. Immunohistochemical staining for IBDV antigen reveals that viral protein localizes predominantly within the cytoplasm of follicular lymphocytes and interfollicular macrophages during this acute phase [7, 35]. Quantitative assessments have demonstrated that apoptosis occurs in upwards of 55.21% of bursal cells during peak infection, a rate significantly higher than that observed in classical strain infections [7].

By 5 to 7 dpi, the histopathological picture evolves into moderate to severe bursitis. The characteristic lesion is a profound depletion of lymphoid follicles, with the loss of demarcation between the cortex and medulla. Infiltration of heterophils and macrophages into the interfollicular connective tissue becomes prominent, accompanied by epithelial hyperplasia and vacuolation of the lining epithelium [24, 40]. The bursal follicle index declines precipitously, with affected follicles showing a collapsed, shrunken appearance and a marked reduction in follicular diameter. The Bursa-to-Body Weight (B/BW) index in nVarIBDV-infected chickens typically falls below the critical threshold of 0.7 by 3 dpi and remains suppressed for the duration of the infection, reflecting the extent of lymphoid mass loss [24, 26].

The chronic phase of nVarIBDV pathogenesis, extending from 14 to 21 dpi, is hallmarked by progressive fibrosis and the replacement of functional lymphoid tissue with stromal elements. Histological examination reveals the formation of epithelial infoldings, follicular cyst formation, and a marked proliferation of interfollicular fibrous connective tissue [24, 35]. Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assays confirm the persistence of DNA fragmentation within the remaining bursal architecture, indicating ongoing apoptotic cell death even weeks after the initial infection [7]. Crucially, this fibrotic remodeling is accompanied by a sustained depletion of B cells, as demonstrated by immunohistochemical analysis using anti-B cell markers such as Bu-1. Quantitative image analysis has shown that B cell density in the BF remains significantly depressed through 21 dpi, a finding that correlates temporally with functional immunosuppression [35].

Mechanisms of Immunosuppression: Beyond B-Cell Lysis

While the direct cytolytic effect of IBDV on bursal B cells is well established, the immunosuppressive phenotype of nVarIBDV is amplified by a complex interplay of cellular and molecular mechanisms that extend beyond simple lymphoid depletion. Transcriptome profiling of the BF at 7 and 14 dpi has unveiled a dynamic host response characterized by the upregulation of genes associated with T-cell exhaustion, immune checkpoint activation, and maladaptive tissue repair [39]. Key findings include the significant downregulation of B-cell receptor signaling components, such as BTK, RAG2, and SYK, which directly impairs the capacity for humoral immune reconstitution [39].

Simultaneously, there is a pronounced upregulation of immune checkpoint molecules, including PD-1, PD-L1, PD-L2, LAG3, and CTLA-4, in the bursa, thymus, spleen, and peripheral blood mononuclear cells following nVarIBDV infection [38]. At 3 dpi, PD-L1 expression in the BF surges by over 6-fold compared to uninfected controls, while PD-L2 expression in the spleen increases by nearly 8-fold by 21 dpi [38]. The concurrent elevation of immunosuppressive cytokines such as TGF-β2 and IL-10 alongside pro-inflammatory mediators like IL-1β and TNF-α creates a microenvironment that is both tolerogenic and conducive to viral persistence [38, 39]. This dysregulated cytokine milieu is hypothesized to facilitate the establishment of a "third signal" that promotes T-cell anergy and exhaustion, thereby preventing an effective adaptive immune response to the virus and potentially to secondary pathogens.

Furthermore, nVarIBDV infection has been shown to impair the efficacy of subsequent vaccinations against other economically significant pathogens. For instance, chickens challenged with a Malaysian nVarIBDV strain (UPM1432/2019) exhibited a statistically significant decline in Newcastle disease virus (NDV) antibody titers by 14 days post-challenge, dropping from approximately 2976 ELISA units in unchallenged controls to 1493 units in infected birds [26]. This phenomenon, termed "immunosuppression-mediated vaccine failure," underscores the insidious nature of nVarIBDV infection, where subclinical bursal damage undermines the protective immunity conferred by routine vaccination programs.

Comparative Pathogenesis: nVarIBDV versus vvIBDV

A critical aspect of understanding nVarIBDV pathogenesis lies in its comparison with the more classical vvIBDV pathotype. While both strains target the bursa, their pathological trajectories diverge significantly. vvIBDV strains, such as HLJ0504, induce a rapid and fulminant infection characterized by high mortality (often exceeding 80%), severe systemic hemorrhages, and multi-organ failure [36]. In contrast, nVarIBDV strains like SHG19 cause no mortality but induce profound bursal atrophy with a B/BW ratio reduction of 70% relative to controls, a level of bursal destruction comparable to or exceeding that of vvIBDV [36, 40]. Histopathologically, vvIBDV-infected bursas show a more intense acute inflammatory response with extensive necrosis and hemorrhage, whereas nVarIBDV-infected bursas exhibit a more protracted course of follicular depletion with robust fibroplasia and cyst formation [40].

This differential pathogenesis is likely attributable to variations in the molecular signaling cascades triggered by each pathotype. vvIBDV infection elicits a more robust and dysregulated pro-inflammatory cytokine response, including higher levels of IL-6 and TNF-α, which contributes to systemic disease and mortality [36]. Conversely, nVarIBDV appears to preferentially activate pathways associated with tissue fibrosis and immune tolerance, including the Hippo, Ras, and cAMP signaling pathways, as inferred from competing endogenous RNA (ceRNA) network analyses of differentially expressed long non-coding RNAs and circular RNAs [39]. This distinct molecular signature may explain the unique ability of nVarIBDV to cause persistent, debilitating immunosuppression without triggering the overt clinical signs that would otherwise alert producers to its presence.

Extended Organ Tropism and Systemic Spread

The pathogenic impact of nVarIBDV is not confined to the bursa. Comprehensive organ tropism studies have demonstrated that the virus can be detected in multiple lymphoid and non-lymphoid tissues, including the spleen, thymus, cecal tonsil, and bone marrow [24, 28, 34]. While the bursa harbors the highest viral load (often exceeding 10⁸ copies/μL at 3 dpi), substantial viral RNA (10⁶ copies/μL or higher) is present in the spleen and thymus, even in the absence of macroscopic lesions [28]. The detection of nVarIBDV in the bone marrow is particularly noteworthy, as this tissue is a site of hematopoiesis and B-cell progenitor development. The presence of lymphoid cell aggregations in the bone marrow of infected chickens suggests a compensatory lymphopoietic response to the peripheral B-cell depletion, but this response is ultimately insufficient to restore immune competence [35].

This multi-organ tropism has direct implications for the pathogenesis of secondary infections. Studies have demonstrated that nVarIBDV infection can exacerbate the pathogenicity of other avian viruses, such as Fowl adenovirus serotype 4 (FAdV-4), by impairing the host's ability to mount an effective antiviral response [30]. Such findings highlight the role of nVarIBDV as a "pathogenic multiplier," where its immunosuppressive effects potentiate the severity of concurrent infections, leading to complex disease presentations and increased economic losses.

The Role of Genetic Reassortment and VP1 in Pathogenesis

While VP2 is the primary determinant of antigenicity and cell tropism, the VP1 polymerase protein, encoded by segment B, plays a crucial yet often underappreciated role in modulating the pathogenic potential of nVarIBDV. Genomic characterization of the A2dB1 genotype has revealed that these strains possess a specific VP1 signature, including residues G24, I141, V163, and E240 [9]. Post-translational modifications of VP1, including phosphorylation at serine 7 mediated by CDK1-cyclin B1 and arginine methylation at R426 mediated by PRMT5, are essential for optimal polymerase activity and viral replication [41, 42]. The cumulative effect of these VP1 polymorphisms and modifications is an enhanced replicative capacity within the bursal microenvironment, enabling nVarIBDV to achieve high viral loads that drive the extensive lymphoid depletion and fibrotic remodeling characteristic of the disease.

In conclusion, the molecular pathogenesis of nVarIBDV is a multi-faceted process orchestrated by specific VP2 mutations that confer B-cell tropism and immune escape, coupled with VP1-driven replicative fitness. The resulting histopathological lesion is not merely a passive lymphoid depletion but an active, progressive process involving apoptosis, T-cell exhaustion, immune checkpoint dysregulation, and fibrotic remodeling, culminating in a state of sustained and profound immunosuppression that undermines poultry health and vaccine efficacy on a global scale.

Epidemiology and Global Emergence of Novel IBDV Genotypes (e.g., A2dB1)

The epidemiological landscape of infectious bursal disease virus (IBDV) has undergone a profound and arguably unprecedented transformation over the past decade, marked by the emergence and transcontinental dissemination of novel variant genotypes, most notably the A2dB1b lineage (also referred to as nVarIBDV). This paradigm shift represents a significant departure from the historical dominance of classical virulent strains and the very virulent IBDV (vvIBDV) pathotypes that have shaped global poultry health strategies since the 1980s [6, 14]. The emergence of these novel variants, characterized by their capacity to induce severe bursal atrophy and profound immunosuppression in the absence of overt clinical mortality, poses a formidable challenge to established vaccination protocols and necessitates a fundamental re-evaluation of global IBDV surveillance and control frameworks.

Origin and Cryptic Emergence in East Asia

The initial emergence and subsequent expansion of the A2dB1 genotype can be traced with considerable precision to East Asia, with China serving as the epicenter of this epidemiological shift. Following decades of co-circulation between classical and very virulent strains, retrospective molecular analyses and longitudinal surveillance studies have indicated that novel variant strains began to appear in Chinese poultry flocks as early as the mid-2010s, with a marked increase in isolation rates documented from 2017 onwards [6, 7, 10]. These early isolates, such as SHG19, ZD-2018-1, and LY21/2, were identified through systematic molecular surveys and were initially characterized by their distinct phylogenetic clustering, divergence from previously described US variant lineages (e.g., Variant E, GLS), and a unique constellation of amino acid substitutions in the VP2 hypervariable region (HVR), including residues such as 252I, 254N, 262Y, 299S, and 318D [2, 10, 13]. The detection of these viruses in immunized flocks across six eastern Chinese provinces provided the first clear evidence that these were not merely laboratory curiosities but represented a significant field threat capable of circumventing vaccine-induced immunity [10].

The cryptic nature of the initial spread was a critical factor in its establishment. Unlike the dramatic clinical signs and high mortality associated with vvIBDV, these novel variants induced a subclinical infection characterized by insidious bursal atrophy and progressive immunosuppression without conspicuous mortality or morbidity [10, 13, 36]. This lack of clinical alarm bells allowed the virus to disseminate undetected within flocks, facilitated by standard poultry management practices, before the scale of the problem was fully appreciated. Longitudinal epidemiological surveys in China from 2023-2024 have since confirmed that nVarIBDV (A2dB1) has become the predominant circulating IBDV genotype, accounting for approximately 69.9% of detected field strains, followed distantly by vvIBDV (16.1%), attenuated vaccine strains (8.6%), and classical strains (5.4%) [21]. This dominance underscores a fundamental shift in the viral ecosystem, driven by intense vaccine-mediated selection pressure.

Molecular Hallmarks of Emergence and Immune Evasion

The rapid and sustained emergence of A2dB1 genotypes is not a stochastic event but is underpinned by specific molecular adaptations that confer a selective advantage in vaccinated populations. The VP2 capsid protein, the primary target of neutralizing antibodies, has undergone critical amino acid changes that drive antigenic drift and immune escape. Notably, the presence of lysine at position 221 (K221) has been identified as a unique antigenic site conserved exclusively in nVarIBDV strains, which alters the local electrostatic potential of the capsid surface and facilitates evasion from antibodies elicited by classical and very virulent strains [9, 22]. Furthermore, residues within the PDE loop (residues 252, 254, and 256) have been experimentally demonstrated to be directly involved in immune escape. Specifically, substitutions V252I, G254N, and I256V, either individually or in combination, markedly reduce antigen-antibody affinity and interfere with serum neutralization, with G254N exerting the most significant effect [31]. This molecular basis of immune evasion explains the consistent observation that commercial vaccines developed against vvIBDV provide poor to incomplete protection against nVarIBDV challenge, with protection rates often falling below 60% in experimental settings [1, 3, 32]. The antigenic cartography of these novel variants confirms they occupy a distinct antigenic cluster, distant from both classical and very virulent strains, highlighting the need for genotype-matched vaccine antigens [44]. Recent in vitro modeling studies further demonstrate that antigenic drift can occur rapidly under sub-neutralizing antibody pressure, with escape mutants arising within as few as five passages, accumulating mutations such as D279Y and G281R in the VP2 HVR [43].

Transcontinental Spread: A Phylodynamic Revolution

Perhaps the most alarming aspect of the A2dB1b epidemiology is its remarkably rapid transcontinental spread. Following its establishment in China, the genotype did not remain geographically confined. Molecular surveillance has documented its progressive dissemination across East and Southeast Asia, with confirmed detections in Malaysia, Japan, and Korea [26, 28, 45]. In Malaysia, the isolation of the UPM1432/2019 strain, genotyped as A2dB1, from vaccinated broiler flocks demonstrated the subclinical yet immunosuppressive impact of the virus, significantly impairing humoral immune responses to subsequent Newcastle disease vaccinations [26]. In Japan, surveillance from 2014 to 2023 revealed the introduction and progressive spread of genogroup A2d strains, initially detected in the western prefectures before expanding eastward, despite the routine application of IBDV vaccination programs [28]. The isolation of the B2977CE2C3 strain confirmed the presence of K221 and I252 residues, hallmarks of the novel variant pathotype [28].

The epidemiological situation escalated dramatically with the detection of A2dB1b strains in regions far beyond Asia. A pivotal molecular survey conducted in Egypt between 2022 and 2023 provided the first confirmed report of this genotype in Africa [37]. The detection of five A2dB1b isolates among samples from twelve governorates signaled a major epidemiological shift in a region historically dominated by very virulent strains [37]. Subsequent investigations across Egypt confirmed the establishment of this genotype, with isolates from 2023 and 2025 showing 100% identity to Chinese strains such as SD-2020 and sharing only 86-90.4% amino acid similarity to commonly used vaccine strains [27, 40, 47]. Critically, phylogenetic analyses of Egyptian isolates revealed that they clustered within the Chinese variant genogroup, suggesting multiple introduction events or a single, well-established founder population [4, 37].

The most dramatic evidence of transcontinental dissemination, however, emerged from South America. Genomic characterization of IBDV strains in Argentina through next-generation sequencing revealed the circulation of A2dB1b genotype viruses exhibiting a high degree of genomic homogeneity and monophyletic clustering with Chinese strains [29]. Phylodynamic reconstructions strongly indicated a single, recent transcontinental introduction event from China to Argentina, a journey spanning over 18,000 kilometers [29]. This finding shattered any assumptions of geographic containment and demonstrated the extraordinary capacity of this genotype for long-distance dissemination, likely facilitated by international trade in poultry products or contaminated fomites. More recent and extensive phylodynamic analyses of the Near East and Persian Gulf region have further corroborated the global spread, confirming the presence of A2dB1b in Jordan, Lebanon, and the United Arab Emirates for the first time, with evidence suggesting separate introduction events from Egypt, East Asia, and even South America, highlighting a complex and interconnected global epidemiology [33].

Evolutionary Drivers and the Reassortment Landscape

The emergence of A2dB1b cannot be viewed in isolation from the broader evolutionary dynamics of IBDV, particularly the role of genomic reassortment. The bisegmented nature of the IBDV genome (segments A and B) allows for the exchange of genetic material between different circulating strains, creating novel combinations with altered pathogenic and antigenic properties. The A2dB1 genotype itself is defined by an A2 segment (encoding the variant VP2) paired with a B1 segment (encoding a classical-like VP1 polymerase). This specific reassortment pattern has been identified as a key driver of the emergence and fitness of these viruses. In Turkey, recent surveillance from 2024-2025 revealed that reassortant A3B1 strains (vvIBDV segment A with B1 segment) had become predominant, highlighting the dynamic nature of segment swapping in shaping local epidemics [16]. Similarly, in Poland, the emergence of A3B1 reassortants added another layer of complexity to the European epidemiological picture [8]. The successful establishment of the A2dB1b genotype suggests that the A2 segment, with its immune-evading VP2, provides a selective advantage, while the B1 segment may confer optimal replication kinetics in the context of the variant capsid. Furthermore, recombination events have been documented, such as in the LY21/2 strain in China, where the major parent was a variant strain and the minor parent a very virulent strain, demonstrating the potential for further genetic diversification [7].

Epidemiological Implications for Global Poultry Health

The epidemiological implications of the global emergence of A2dB1 are profound and multifactorial. First, the inability of current commercial vaccines to provide sterilizing immunity against these variants has created a scenario where vaccinated flocks remain susceptible to infection, albeit with reduced clinical signs [1, 46]. This leads to persistent viral circulation within poultry populations, with the attendant risks of further antigenic drift and the evolution of even more resistant strains. The subclinical nature of the infection masks the true economic burden, which is manifested through impaired growth performance, increased susceptibility to secondary pathogens (such as Fowl adenovirus serotype 4), and, critically, the suppression of immune responses to other essential vaccinations, including Newcastle disease virus [26, 30]. Second, the broad tissue tropism of nVarIBDV, including the thymus, spleen, cecal tonsils, and bone marrow, in addition to the bursa of Fabricius, indicates a more systemic infection than previously appreciated, contributing to a prolonged and multifaceted state of immunosuppression [24, 28, 35]. Histopathological examinations reveal not only B cell depletion but also long-lasting structural damage to the bursa, including follicular loss, fibrosis, and replacement by epithelial reticular cells, resulting in chronic immunodeficiency [35]. Third, the global dispersion of this genotype, now confirmed on three continents (Asia, Africa, and South America) and encroaching on Europe and the Middle East, underscores the inadequacy of national or regional control strategies and demands an internationally coordinated response [29, 33]. The detection of a new, distinct amino acid signature (S215N, S317R, G322E, E323D) in emerging US variant strains in the Delmarva peninsula, which was shown to significantly reduce virus neutralization titers, suggests that convergent evolutionary pressures are generating immune-escape variants even in regions where the A2dB1 genotype has not yet been officially reported, underscoring the global nature of this threat [5]. The epidemiological trajectory of the A2dB1b genotype serves as a stark reminder of the capacity of RNA viruses to exploit ecological and immunological niches, driven by a combination of inherent genetic plasticity and anthropogenic selection pressures.

Genetic Diversity and Phylogenetic Analysis of the VP2 Gene in IBDV Variants

The hypervariable region (HVR) of the VP2 capsid gene constitutes the primary molecular determinant of antigenic diversity, immune evasion, and phylogenetic classification for infectious bursal disease virus (IBDV). As a double-stranded RNA virus belonging to the family Birnaviridae, IBDV exhibits a remarkable propensity for genetic variation through accumulated point mutations, recombination events, and segment reassortment, all of which are prominently reflected in the VP2 gene sequence [6, 14]. The VP2 protein forms the outer capsid shell and contains the major neutralizing epitopes recognized by the host humoral immune system; consequently, even single amino acid substitutions within its HVR can profoundly alter antigenicity, virulence, and vaccine breakthrough potential [31, 43]. The last decade has witnessed an unprecedented expansion in the genetic diversity of IBDV field strains globally, driven largely by intensive vaccine pressure, high flock density, and the inherent error-prone replication of the viral RNA-dependent RNA polymerase [8, 23]. This section provides an exhaustive analysis of the genetic diversity characterizing circulating IBDV variants, with a particular focus on the phylogenetic relationships, signature amino acid motifs, and evolutionary trajectories revealed through systematic VP2 gene surveillance.

Molecular Basis of Genetic Diversity in the VP2 Gene

The VP2 gene spans approximately 1,356 nucleotides and encodes a 452-amino-acid precursor protein that is subsequently cleaved to yield the mature capsid protein. Within VP2, the hypervariable region, located between residues 206 and 350, harbors four hydrophilic loops (PBC, PDE, PF, and PHG) that are exposed on the virion surface and constitute the principal antigenic domains [31, 50]. These loops are the primary targets of virus-neutralizing antibodies, and selective pressure from vaccine-induced immunity drives the accumulation of amino acid changes in these regions, a process formally referred to as antigenic drift [43]. Asfor et al. [43] elegantly demonstrated this phenomenon in vitro by serially passaging a classical genogroup A1 strain (F52/70) in the presence of sub-neutralizing concentrations of sera from birds vaccinated with the 2512 strain. By passage 10, escape mutants harboring mutations D279Y, G281R, S251I, and D279N emerged, confirming that single amino acid changes in the HVR are sufficient to confer resistance to neutralizing antibodies [43]. Notably, the D279Y mutation appeared as early as passage 5, indicating that antigenic drift can occur rapidly under immune selection [43].

Field-based molecular surveillance corroborates these laboratory findings and reveals that contemporary IBDV variants possess a constellation of amino acid substitutions that collectively reshape the antigenic landscape. In the United States, Egana-Labrin et al. [5] conducted a comprehensive molecular characterization of IBDV strains circulating in the Delmarva region (Delaware, Maryland, and Virginia) from 2018 to 2023. Sequence analysis of the VP2 HVR from 53 bursal samples identified an amino acid signature absent in the prototype variant E strain: S215N, S317R, G322E, and E323D. This signature was present in 34 of 53 (64%) of the sequenced strains, representing a marked increase from the 25% prevalence documented in 2007 strains from the same region [5]. Critically, virus neutralization assays demonstrated that sera raised against the Del-E variant exhibited significantly reduced neutralizing titers against strains carrying this emerging signature (P < 0.05), providing direct evidence that these substitutions drive immune escape [5]. This finding underscores the dynamic nature of IBDV antigenic evolution and highlights the necessity for continuous antigenic monitoring to inform vaccine strain selection.

Phylogenetic Classification and Emergence of Novel Genogroups

The genetic classification of IBDV has undergone substantial refinement over the past decade, culminating in a standardized genotyping system based on nucleotide sequences of both segment A (which encodes VP2, VP3, VP4, and VP5) and segment B (which encodes VP1, the RNA-dependent RNA polymerase) [14]. Jackwood et al. [14] proposed a nomenclature wherein genogroups are designated by a letter (A for segment A, B for segment B) followed by a number, with increasing numbers reflecting greater genetic divergence from the classical serotype 1 strains. Under this system, classical virulent strains are classified as A1B1, very virulent strains as A3B2, and the North American antigenic variants are organized into genogroups A2a (variant E), A2b (9109), and A2c (GLS) [5, 14]. However, the most consequential development in IBDV phylogeny has been the emergence and global spread of the novel variant genogroup A2dB1 (also designated A2dB1b), which now constitutes a dominant lineage across multiple continents.

The novel variant IBDV (nVarIBDV) was first identified in China in the mid-2010s, following a prolonged period of subclinical circulation and cumulative mutation accumulation [6, 10]. Fan et al. [10] reported the initial detection of these variants in six eastern Chinese provinces and demonstrated that they were genetically distinct from both American variant strains and contemporary very virulent strains, with less than 97.7% amino acid identity in VP1 and 98.7% in VP2. Subsequent comprehensive epidemiological surveys confirmed that nVarIBDV strains possess a characteristic set of amino acid residues that distinguish them from earlier genogroups. Zhu et al. [2] analyzed 31 IBDV isolates collected from broiler chickens in southern China during 2023 and identified 12 novel variant strains exhibiting the signature residues 252I, 254N, 262Y, 299S, and 318D. These residues differ markedly from the classical variant motif (222T, 249K, 286I) and the very virulent motif (222A, 242I, 256I, 294I) [2, 21]. The phylogenetic tree constructed in that study placed the novel mutants in a distinct lineage separate from variant E and GLS, confirming that they represent an evolutionarily divergent cluster that has emerged under intense vaccine selection pressure [2].

Global Phylodynamics and Transcontinental Spread of A2dB1 Strains

Perhaps the most striking feature of nVarIBDV epidemiology is the unprecedented speed and breadth of its geographic expansion. After its emergence in China, the A2dB1 genotype rapidly disseminated across East and Southeast Asia, reaching Japan, Malaysia, and Korea within a few years [26, 28, 45]. Takahashi et al. [28] documented novel antigenic variant strains in Japan from 2014 to 2023, with the B2977CE2C3 isolate exhibiting the characteristic A2d-specific residues K221 and I252 in the VP2 projection domain. By 2023, these strains were detected in both western and eastern Japan despite routine vaccination, indicating that they had become firmly established in the field [28]. Similarly, Dastjerdi et al. [26] characterized a Malaysian nvIBDV strain (UPM1432/2019) as genotype A2dB1 and showed that it caused subclinical bursal atrophy and significantly impaired Newcastle disease vaccine efficacy in broiler chickens, highlighting the practical consequences of immunosuppression induced by these variants.

The transcontinental jump of A2dB1 from Asia to Africa was confirmed by Legnardi et al. [37], who reported the first detection of A2dB1b strains in Egypt during 2022–2023. Among 24 samples collected across twelve Egyptian governorates, five were identified as novel variant strains, marking the first time this genotype had been documented outside of Eastern and Southern Asia [37]. This finding was corroborated by Salaheldin et al. [27], who isolated nVarIBDV from 18 vaccinated chicken flocks in Egypt and demonstrated that the VP2 sequences of these isolates shared 100% identity with the Chinese SD-2020 strain and 99.5–98.1% similarity to ZD-2018-1, QZ, GX, and SG19 strains. The implications for vaccine efficacy are profound: the Egyptian variant strains exhibited only 86–90.4% amino acid similarity to commonly used vaccine strains (Faragher 52/70, V217, and Indian strains), a genetic gap that translates into significant antigenic mismatch and reduced cross-protection [27, 37].

The most recent and alarming development is the detection of A2dB1b in South America. Tomás et al. [29] applied next-generation sequencing to 18 Argentine IBDV isolates and obtained complete coding sequences for both genome segments. Phylogenetic analysis revealed that all Argentine viruses belonged to the A2dB1b genotype and formed a monophyletic cluster with high bootstrap support, indicating a single introduction event from China [29]. The estimated timing of this introduction, combined with the high genomic homogeneity among Argentine strains, suggests a very recent incursion, likely within the past few years [29]. Phylodynamic reconstruction by Poletto et al. [33] further refined this picture, revealing that the Near East and Persian Gulf region experienced multiple independent introductions of A2dB1b from Egypt, East Asia, and even South America between November 2023 and November 2024. In that survey, 55 of 138 flocks (39.9%) were positive for field strains, with A2dB1b identified for the first time in Jordan, Lebanon, and the United Arab Emirates [33]. These data collectively indicate that nVarIBDV has achieved a genuinely pandemic distribution, facilitated by global trade in poultry products and the movement of infected birds or contaminated fomites.

Key Amino Acid Determinants of Antigenic Shift and Immune Escape

The molecular basis for the immune evasion exhibited by nVarIBDV has been progressively elucidated through reverse genetics, monoclonal antibody mapping, and structural modeling. A landmark study by Xiong et al. [22] generated a monoclonal antibody (mAb 5B5) that specifically recognized nVarIBDV strains but not classical, very virulent, or attenuated viruses. Epitope mapping and site-directed mutagenesis identified residue 221K in VP2 as the critical antigenic determinant, a residue that is conserved exclusively in nVarIBDV strains. When lysine (K) at position 221 was mutated to glutamine (Q), the residue found in classical and very virulent strains, the reactivity of mAb 5B5 was abolished, and the mutated virus became susceptible to neutralization by sera raised against very virulent or classical viruses [22]. Structural modeling revealed that 221K is surface-exposed on the VP2 projection domain and alters the local electrostatic potential, thereby facilitating immune evasion by disrupting antibody–antigen interactions [22]. This residue is now considered a definitive molecular marker for nVarIBDV and is routinely used for genotyping.

Building on this work, Wang et al. [31] systematically investigated the roles of residues in the PDE loop (residues 249–260) in immune escape. Using an immunofluorescence-based antigen–antibody affinity assay, they demonstrated that mutations V252I, G254N, and I256V, either individually or in combination, significantly reduced the binding affinity of very virulent IBDV antiserum to the VP2 protein. Among these, G254N had the most pronounced effect, followed by V252I and I256V [31]. Recombinant viruses harboring these point mutations were rescued by reverse genetics, and neutralization assays confirmed that the mutations independently and synergistically conferred resistance to antibody-mediated neutralization [31]. The epidemiological significance of these findings is immense: the residues 252I, 254N, and 256V are now standard in virtually all nVarIBDV field isolates, providing a molecular explanation for the failure of very virulent IBDV vaccines to protect against these variants [3, 31, 40].

Recombination and Coexistence of Multiple Genotypes

The genetic diversity of IBDV is further amplified by recombination events, which can generate chimeric viruses with novel antigenic and pathogenic properties. Huang et al. [7] isolated strain LY21/2 from a farm in Shandong Province, China, and demonstrated that it arose from a recombination event in which a variant strain (19D69) served as the major parent and a very virulent strain (Harbin-1) provided a minor segment. Phylogenetic analysis placed LY21/2 within the novel variant branch, yet the recombination had introduced very virulent-derived sequences that potentially altered its biological behavior [7]. Although LY21/2 caused no clinical signs or mortality, it induced bursal atrophy and apoptosis in 55.21% of bursal cells, highlighting how recombination can produce viruses with intermediate pathogenic profiles [7].

Epidemiological surveys across multiple countries consistently reveal the coexistence of multiple IBDV genotypes within the same geographic region, often within the same flock. In China, Yu et al. [21] conducted a nationwide survey from 2023 to 2024 and identified four coexisting pathotypes: nVarIBDV (69.9% of positive samples), very virulent IBDV (16.1%), attenuated IBDV (8.6%), and classical IBDV (5.4%). Notably, all 15 very virulent strains detected in this study carried single or combined mutations in the VP2 HVR, including D279N, G254D/I256L/D279N, or A222T/G254D/I256L/D279N [21]. These mutated very virulent strains (designated mvvIBDV) were genotypically classified as very virulent but exhibited subclinical atypical IBD symptoms, blurring the traditional distinction between pathotypes [21]. In Turkey, Bayraktar et al. [16] characterized 35 IBDV strains from vaccinated flocks during 2024–2025 and identified three cocirculating genotypes: reassortant A3B1 strains (predominant), classical A1B1 strains, and very virulent A3B2 strains. The reassortant A3B1 strains had a segment A derived from very virulent parents, but a segment B from classical parents, potentially altering their virulence and transmissibility [16]. Similarly, Pikuła et al. [8] documented the dynamic epidemiological situation in Poland, where very virulent strains (A3B2) and reassortants of genotypes A3B4 and A3B1 were co-circulating, the latter representing newly introduced lineages to the region.

In Egypt, the epidemiological landscape has become increasingly complex with the introduction and establishment of nVarIBDV alongside endemic very virulent strains. Alkhalefa et al. [49] analyzed VP2 sequences from Nile Delta broiler flocks and found that six of seven sequenced isolates were closely related to very virulent reference strains (Giza 2000, Giza 2008), while one isolate clustered with the classical D78 vaccine strain. More recent work by Elkohely et al. [47] examined 34 vaccinated flocks in Beheira and Menoufia provinces during 2025 and found that 15 (44.1%) were IBDV-positive, with 10 classified as variant strains and 5 as very virulent strains. The variant strains possessed residues K221, I252, N254, A270, and S299, all associated with immune escape, while one very virulent strain harbored the I256L mutation, which may further contribute to antigenic drift [47]. The overall antigenic diversity between field strains and vaccine strains ranged from 3.7% to 12.3%, raising serious concerns about the efficacy of current vaccination programs [47].

Evolutionary Rates and Population Dynamics

Phylodynamic analyses provide quantitative insights into the evolutionary forces shaping IBDV diversity. Fraga et al. [48] applied Bayesian Markov chain Monte Carlo methods to reconstruct the evolutionary history of Brazilian antigenic variants (genogroup G4, now A2). Their analysis estimated that the ancestor of these variants was introduced into South America around 1968 (95% highest posterior density [HPD]: 1960–1974) and into Brazil around 1974 (95% HPD: 1968–1977), with the most likely source being Eastern Europe (Hungary or Poland) [48]. The Brazilian variants exhibited a conserved amino acid pattern (S222, T272, P289, I290, F296) that distinguished them from other genogroups, suggesting that the lineage has evolved independently for approximately five decades following its introduction [48].

For the nVarIBDV lineage, population

Diagnostic Approaches for IBDV Variants: DIVA Strategies, qRT-PCR, and Histopathology

The emergence and global dissemination of novel variant infectious bursal disease virus (nVarIBDV) strains, particularly those belonging to genotype A2dB1b, have fundamentally challenged the established paradigms for both diagnosis and disease control [1, 4, 29, 37]. These variants, characterized by their subclinical yet profoundly immunosuppressive nature, often circulate undetected within vaccinated flocks, precipitating vaccine failures and imposing significant economic losses [3, 10, 30]. Consequently, the diagnostic armamentarium has had to evolve rapidly, moving beyond simple virus detection to sophisticated approaches capable of differentiating infected from vaccinated animals (DIVA), precisely quantifying viral loads, and characterizing the nuanced histopathological lesions that define these infections. A robust, integrated diagnostic strategy, combining DIVA-capable molecular tools, high-resolution quantitative PCR, and meticulous histopathological evaluation, is now indispensable for epidemiological surveillance, vaccine efficacy assessment, and the rational design of control programs.

Differentiating Infected from Vaccinated Animals: The DIVA Imperative

The cornerstone of any effective control program for IBDV, particularly in the context of widespread vaccination, is the capacity to reliably distinguish between field virus infection and vaccine-induced immunity. This DIVA capability is not merely an academic exercise; it is a critical operational requirement. The failure of many commercial vaccines, including live viral vector, VP2 subunit, and immune-complex vaccines, to provide sterile immunity against nVarIBDV strains [1, 3, 32] means that vaccinated birds can still become infected and shed the virus, creating a diagnostic blind spot. Traditional serological methods, such as ELISA and virus neutralization tests, are inadequate for this purpose because they measure total antibody responses and cannot differentiate antibodies elicited by vaccination from those generated by natural infection [17, 51].

The most robust DIVA strategies for IBDV leverage the genetic and antigenic divergence of the nVarIBDV variants. A primary approach relies on molecular detection of the virus itself, specifically targeting genomic regions that are absent or highly divergent in vaccine strains. The vast majority of current commercial IBDV vaccines are based on classical virulent (cvIBDV), very virulent (vvIBDV), or attenuated (attIBDV) strains, whose VP2 hypervariable region (HVR) sequences differ markedly from those of the novel variant genogroups [3, 27, 47]. For instance, Wang et al. [1] explicitly used qRT-PCR as a DIVA tool to confirm that vaccinated chickens challenged with nVarIBDV (FJ2019-01 strain) were indeed infected, demonstrating that the molecular assay could differentiate between the vaccine virus and the challenge virus. This is possible because the primers and probes can be designed to amplify a conserved region of the IBDV genome, or more specifically, to target signature mutations unique to the variant strains.

A more refined molecular DIVA strategy involves the use of high-resolution melting curve (HRM) analysis coupled with qRT-PCR. As detailed by Wang et al. [52], an HRM-qRT-PCR assay was developed that can simultaneously identify and pathotype vvIBDV, nVarIBDV, and attIBDV in a single reaction. This method exploits the distinct GC content of a specific region within segment A (nucleotides 2450–2603) across the three pathotypes. The melting temperature (Tm) of the amplicon is directly correlated with its GC content, generating distinct, easily distinguishable melting peaks for each virus type. This provides an elegant, single-step solution for both detection and pathotyping, effectively functioning as a molecular DIVA tool by differentiating field strains (vvIBDV, nVarIBDV) from commonly used live attenuated vaccine strains (attIBDV). The specificity of this method is exceptionally high, showing no cross-reactivity among the three pathotypes or with other common avian pathogens [52].

Furthermore, the identification of unique antigenic sites on the VP2 protein of nVarIBDV offers a promising avenue for serological DIVA. The work of Xiong et al. [22] demonstrated that the amino acid residue lysine at position 221 (K221) is a conserved and unique antigenic site exclusively present in nVarIBDV strains. A monoclonal antibody (mAb 5B5) raised against the VP2-HVR of nVarIBDV specifically recognized this conformational epitope, reacting with nVarIBDV but not with cvIBDV, vvIBDV, or attIBDV [22]. This finding opens the door to the development of a serological DIVA test, such as a competitive ELISA, that would detect antibodies specifically directed against this nVarIBDV-specific epitope. Such a test would allow for the serological identification of flocks that have been naturally infected with nVarIBDV, even in the presence of antibodies from vaccination. While still in the developmental phase, this approach represents a significant conceptual advance, moving beyond nucleic acid detection to the immunological fingerprint of the virus.

Virological Confirmation and Quantification: The Role of qRT-PCR

Quantitative real-time reverse transcription PCR (qRT-PCR) has become the gold standard for the rapid, sensitive, and specific detection of IBDV RNA, superseding conventional RT-PCR in most diagnostic and research settings. Its utility extends far beyond simple presence-or-absence detection; it provides critical quantitative data on viral load, which correlates with pathogenic potential, tissue tropism, and the dynamics of infection. The diagnostic sensitivity of qRT-PCR is particularly vital for detecting nVarIBDV, which is often present in high copy numbers within target organs despite the absence of overt clinical signs [24, 28].

The extreme tropism of nVarIBDV for the bursa of Fabricius (BF) makes this tissue the sample of choice for diagnostic testing. Studies consistently report the highest viral loads in the BF, frequently exceeding 10⁸ to 10¹² copies per gram of tissue [24, 28, 34]. Hair-Bejo et al. [24] demonstrated that in commercial broilers, the viral copy number in the BF was significantly higher than in other lymphoid tissues such as the thymus, spleen, cecal tonsil, and bone marrow, establishing a clear hierarchy of tissue tropism. The detection of the virus in a wide array of tissues, including the bone marrow, which is not a typical site of IBDV replication, underscores the systemic nature of the infection and the utility of sampling multiple tissues if the BF is unavailable [24, 34]. The high viral load in the BF is also observed in experimentally infected SPF chickens, where it persists for at least 21 days post-infection, indicating a prolonged period of active viral replication [34].

The advent of HRM-qRT-PCR represents a paradigm shift in IBDV molecular diagnostics [52]. By integrating pathotyping with quantification, this single-tube assay can determine not only the presence of IBDV but also the specific pathotype (nvIBDV, vvIBDV, or attIBDV) and the viral copy number. The method's ability to detect and differentiate co-infections with multiple IBDV pathotypes, which are a common occurrence in the field [6, 21, 52], is a major advantage over conventional qRT-PCR. For example, a flock could be co-infected with a vvIBDV strain causing mortality and an nVarIBDV strain causing subclinical immunosuppression, a scenario that would be impossible to disentangle with conventional assays. The HRM-qRT-PCR method would produce distinct melting peaks for each virus, providing a comprehensive picture of the circulating viral quasispecies [52]. Its detection limit of 61-67 copies/μL and 100% accuracy in co-infection models make it an exceptionally powerful tool for real-time large-scale epidemiological surveillance [52].

Histopathological Assessment: Defining the Lesion

While molecular techniques provide evidence of viral presence and identity, histopathological examination of the bursa of Fabricius remains an indispensable tool for characterizing the severity and nature of the pathological insult. Histopathology provides the direct, visual evidence of the functional damage inflicted by the virus, a piece of information that quantitative PCR alone cannot provide. The histopathological signature of nVarIBDV infection is a distinct, progressive, and ultimately severe lymphocytolytic and atrophic process.

The hallmark lesion of nVarIBDV infection is a severe, non-inflammatory atrophy of the BF, characterized by progressive lymphoid follicle depletion [3, 7, 27, 35, 40]. This is in stark contrast to the acute, hemorrhagic, and necrotizing bursitis typically seen with classical vvIBDV strains [36, 40]. In nVarIBDV-infected chickens, the initial stages (3–5 days post-infection, dpi) are marked by mild to moderate edema and swelling, with the first signs of lymphocyte depletion in the medullary and cortical regions of the follicles [24, 35]. By 7 dpi, the lymphocyte depletion becomes severe, with follicles becoming shrunken, distorted, and hypocellular. The interfollicular connective tissue undergoes hyperplasia and fibrosis, leading to a loss of the normal follicular architecture [7, 35, 40]. By 14–21 dpi, the bursa is markedly atrophic, with a loss of follicular structure, the presence of cystic cavities, epithelial infoldings, and replacement of lymphoid cells by a network of reticular epithelial cells and fibrous connective tissue [35, 40]. The bursa-to-body weight ratio (BBR) decreases precipitously, often to less than 0.7, confirming the profound atrophy [24, 28].

The severity of the histopathological lesions is a direct reflection of the virus's immunosuppressive capacity. The TUNEL assay has demonstrated that the lymphocyte depletion is driven by apoptosis, with up to 55% of bursal cells undergoing programmed cell death in nVarIBDV-infected chickens [7]. This is a key distinction from the necrosis seen in vvIBDV infection. Immunohistochemical staining using monoclonal antibodies against viral antigens, such as VP2, confirms the presence of IBDV-positive cells, predominantly within the depleted follicles of the BF and cecal tonsils during the acute phase [7, 35]. The depletion is not limited to B cells. Takahashi et al. [28] and Ito et al. [35] demonstrated that the depletion of B cells in the BF is profound and long-lasting, persisting for up to 21 dpi, which explains the profound and sustained humoral immunosuppression. Additionally, the depletion of T cells in the thymic cortex and the increased expression of immune checkpoint molecules, such as PD-1, PD-L1, and CTLA-4, observed via transcriptomic analysis, suggest a T cell exhaustion phenotype that further compromises the adaptive immune response [35, 38, 39]. This dual B- and T-cell dysfunction explains why infected flocks are highly susceptible to secondary infections and exhibit poor responses to subsequent vaccinations, such as those against Newcastle disease [26]. A standardized histopathological scoring system, as described by the World Organisation for Animal Health (WOAH), is crucial for comparing lesion severity across studies and for vaccine efficacy trials [44]. Scoring typically ranges from 0 (normal) to 4 (severe depletion with atrophy), providing a semi-quantitative measure of the pathological damage.

Vaccination Strategies and Protective Efficacy Against Novel IBDV Variants

The emergence and rapid global dissemination of novel variant infectious bursal disease viruses (nVarIBDV), particularly those belonging to genotype A2dB1b, have fundamentally challenged the foundational principles of IBDV control through vaccination. For decades, the global poultry industry relied on a triad of vaccine platforms, live attenuated, immune-complex, and inactivated oil-emulsion vaccines, derived from classical virulent or very virulent strains (vvIBDV). These vaccines successfully mitigated clinical disease and mortality associated with vvIBDV but have demonstrated a pronounced and concerning inability to provide sterilizing immunity or even adequate protection against the antigenically distinct nVarIBDV strains [1, 3, 23, 46]. This section provides an exhaustive analysis of the multifaceted vaccination strategies evaluated against nVarIBDV, dissecting the immunological mechanisms of vaccine failure, the variable efficacy observed across different vaccine platforms and regimens, and the promising avenues being pursued for next-generation, genotype-matched vaccines.

The Paradigm of Vaccine Failure: Antigenic Mismatch and Immune Escape

The cornerstone of the failure of existing vaccines to protect against nVarIBDV lies in a profound antigenic mismatch. The VP2 capsid protein, the primary target for neutralizing antibodies, exhibits a distinct amino acid signature in nVarIBDV strains compared to classical and very virulent strains. Specifically, residues at positions 221 (K), 252 (I), 254 (N), 299 (S), and 318 (D) are characteristic of the A2dB1 genotype and are situated within or adjacent to critical neutralizing epitopes, particularly the PBC and PDE loops of the VP2 hypervariable region (HVR) [2, 9, 22, 31]. This antigenic drift is not a random occurrence but is driven by intense immune selection pressure from widespread vaccination [5, 16, 43]. As demonstrated by in vitro modeling, the serial passage of IBDV in the presence of sub-neutralizing concentrations of vaccine-induced antibodies rapidly selects for escape mutants harboring mutations in the VP2 HVR, such as D279Y and G281R, effectively mimicking the evolutionary trajectory observed in the field [43]. Deep antigenic cartography has further confirmed that nVarIBDV strains occupy a distinct antigenic cluster, separate from both classical and very virulent strains, confirming that the serological response elicited by current vaccines is suboptimally matched to these emerging variants [44]. This phenomenon has been observed across continents. In China, early studies verified that nVarIBDV could severely damage the bursa of Fabricius in chickens immunized with vvIBDV vaccines, directly correlating the antigenic mismatch with vaccine breakthrough [3]. Similarly, surveillance in the Delmarva region of the United States identified an emerging amino acid signature (S215N, S317R, G322E, E323D) in circulating variant strains that was associated with a significant reduction in the virus neutralization titer of sera raised against the classic Delaware E (Del-E) strain, providing direct evidence of ongoing antigenic drift leading to immune escape within a vaccinated population [5].

Efficacy of Conventional Platform Vaccines Under Booster Regimens

Initial assessments of commercial vaccines, including live viral vector vaccines, VP2 subunit vaccines, and immune-complex vaccines, administered as a single dose at one day of age demonstrated catastrophic failure, offering negligible protection against nVarIBDV challenge [1, 46]. This finding set a new critical benchmark: the standard single-dose vaccination protocols employed against vvIBDV are inadequate for controlling nVarIBDV. However, a more nuanced picture emerged from rigorous investigations into booster immunization strategies. Wang et al. (2024) demonstrated that while a single dose of a live viral vector, VP2 subunit, or immune-complex vaccine was ineffective, the addition of a secondary booster vaccination with a live classical strain (e.g., B87 or W2512 G-61) could dramatically elevate protection levels [1]. In specific-pathogen-free (SPF) chickens, priming with a live viral vector or immune-complex vaccine followed by a B87 booster conferred at least 80% protection against the FJ2019-01 nVarIBDV strain. For broilers, a similar regimen using a VP2 subunit or immune-complex vaccine followed by a W2512 G-61 booster also achieved >80% protection. This suggests that, despite the antigenic mismatch, a prime-boost strategy can generate a sufficiently broad and high-titer antibody response to partially overcome the immune evasion of nVarIBDV [1]. Yet, the same study highlighted the inconsistency of this approach; the combination of a live viral vector prime followed by a W2512 G-61 booster yielded only poor to moderate protection in broilers, indicating that the efficacy of such cross-protective strategies is highly dependent on the specific vaccine platforms used and the host's genetic and immunological background [1].

Further complicating the picture, other independent investigations have painted a less optimistic picture. Aliyu et al. (2024) evaluated immune-complex (Vaccine A) and attenuated live (Vaccine B) vaccines in SPF chickens challenged with a Malaysian nVarIBDV (UPM1432/2019). Neither vaccine provided full protection; both induced significant bursal damage and atrophy post-challenge, despite the presence of measurable antibody titers. The bursal lesion scores in the vaccinated-challenged groups were significantly higher than in unchallenged controls, reinforcing the concept that current vaccines cannot prevent bursal pathology [46]. This is consistent with findings from China, where even booster immunization with various commercial vaccines could only raise protection rates to between 60% and 80%, falling short of the 100% protection considered optimal for economic control [32]. The World Organisation for Animal Health (WOAH) and the Food and Agriculture Organization (FAO) have long recognized IBD as a major constraint to poultry production, and these findings underscore a growing global threat to food security and the sustainability of poultry operations, as the core preventative tool is being rendered partially ineffective by viral evolution.

Development and Evaluation of Genotype-Matched Inactivated Vaccines

The unequivocal conclusion from the failure of conventional cross-protective strategies is that a true solution requires genotype-matched vaccines. A landmark study by Wang et al. (2024) provided definitive proof of this concept by preparing oil-emulsion inactivated vaccines (OEVs) from two distinct nVarIBDV isolates, QZ191002 and YL160304 [32]. Vaccination-challenge experiments in SPF chickens revealed a stark contrast: while commercial vaccines (even with boosters) could at best achieve 80% protection, the OEVs made from homologous nVarIBDV strains provided 100% protection against a homologous challenge. This was characterized by high-level specific antibodies, complete amelioration of bursal damage, and a significant reduction in viral load. Critically, one of the nVarIBDV OEVs (YL160304) even provided 100% cross-protection against a heterologous nVarIBDV strain, suggesting that a carefully selected single nVarIBDV strain could serve as a broad-spectrum vaccine candidate for this genogroup [32]. Further supporting this approach, an inactivated nVarIBDV vaccine candidate evaluated in broiler chickens demonstrated both safety and efficacy. The booster group (vaccinated at day-old and again at day 14) showed significantly higher bursa-to-body weight ratios and stronger antibody responses post-challenge compared to non-boosted or control groups, indicating that a homologous inactivated vaccine is not only safe but can induce robust, protective immunity, especially with a multi-dose regimen [55]. These results establish a clear strategic pathway: the development and licensing of inactivated or subunit vaccines incorporating the VP2 of currently circulating nVarIBDV strains is the most direct and reliable route to achieving field-level control.

Second-Generation and Novel Vector-Based Vaccination Platforms

The failure of traditional live vaccines to provide a wide safety margin against immunosuppression and bursal atrophy, coupled with the antigenic mismatch, has accelerated the development of next-generation platforms. These technologies offer the promise of antigenic precision, improved safety profiles, and the potential for bivalent or multivalent protection. A prominent strategy is the use of herpesvirus of turkeys (HVT) as a live viral vector. HVT is naturally apathogenic in chickens and can be administered in ovo or at hatch, providing a long-lasting platform for delivering foreign antigens. A recombinant HVT expressing the VP2 gene of a Korean nVarIBDV (G2d), constructed using CRISPR/Cas9 technology, demonstrated 100% protection against bursal atrophy (BBIX > 1.0) after challenge, in stark contrast to a commercial vaccine A which provided only 40% protection [45]. This highlights the superior precision of a vector designed from the ground up to match the target antigen.

The Newcastle disease virus (NDV) backbone has also been exploited for bivalent vaccine development. A recombinant LaSota strain NDV expressing the VP2 of the nVarIBDV SHG19 strain (rLaS-VIIF/HN-VP2) induced full protection against both lethal genotype VII NDV and IBDV challenge in a single dose [53]. However, the impact of pre-existing maternal antibodies against the NDV vector on vaccine take remains a practical concern. More sophisticated chimeric NDV vectors, such as rHV and rLHV which incorporate genotype VII F and HN genes for better antigenic match, have also shown robust humoral and cellular immunity against both nVarIBDV and NDV in SPF chickens, representing a significant step forward in simplifying vaccination schedules and enhancing flock-level protection against two major immunosuppressive pathogens [54].

The Frontier of DNA and Multiepitope Vaccines

At the leading edge of vaccine technology, DNA vaccines and immunoinformatics-driven designs are being explored. The first lipid nanoparticle (LNP)-encapsulated VP2 DNA vaccine (pCASHGVP2-LNP) against nVarIBDV was recently reported. This approach uses a eukaryotic expression plasmid to deliver the VP2 gene of the SHG19 strain directly into host cells, where it is expressed endogenously. Vaccination of SPF chickens with pCASHGVP2-LNP induced specific neutralizing antibodies after a double immunization and provided protection against nVarIBDV challenge, marking a critical proof-of-concept for a non-replicating, genetically defined vaccine platform that can be rapidly updated as the virus evolves [50]. Looking further ahead, reverse vaccinology has been applied to design a multiepitope vaccine candidate incorporating B-cell, CD4+, and CD8+ T-cell epitopes from VP2 and VP3. This computationally designed construct is predicted to be stable, antigenic, and immunogenic, with strong binding affinity to Toll-like receptor-3. While still requiring in vivo validation, such approaches offer a radical alternative, potentially providing broad, cell-mediated as well as humoral immunity without the risks associated with live virus platforms [58].

Immunomodulation and Adjuvant Strategies to Enhance Vaccine Efficacy

In parallel with antigen design, there is a growing appreciation for the role of immunomodulation and advanced adjuvants in overcoming the profound immunosuppression induced by nVarIBDV. As has been comprehensively demonstrated, infection with nVarIBDV leads to a severe upregulation of immune checkpoint molecules (PD-1, PD-L1, CTLA-4, LAG3) in the bursa of Fabricius, thymus, and spleen, creating a state of T-cell exhaustion and B-cell depletion that directly undermines vaccine-induced immunity [38, 39]. This mechanistically explains why vaccination strategies that rely solely on humoral immunity can fail. Strategies to counter this include the use of non-specific immunostimulants such as chicken transfer factor (TF). Administration of TF has been shown to effectively alleviate nVarIBDV-induced growth retardation and bursal atrophy and markedly inhibit viral replication in the bursa [56]. This suggests that bolstering innate and adaptive immune responses prior to, or concurrent with, vaccination may be a viable adjunctive strategy. Furthermore, the integration of nano-adjuvants, such as lipid nanoparticles, polymeric systems, and Toll-like receptor agonists, into vaccine formulations is a transformative area of research. These systems can enhance antigen stability, promote targeted delivery to antigen-presenting cells, and orchestrate a more balanced Th1/Th2 response, leading to more robust and durable protection against antigenically diverse and immunosuppressive IBDV variants [57]. The incorporation of such advanced adjuvant technologies into genotype-matched vaccines is likely to be essential for achieving the level of flock immunity required to halt the transmission and economic impact of nVarIBDV globally.

References

[1] Wang C, Hou B. The booster immunization using commercial vaccines effectively protect chickens against novel variants of infectious bursal disease virus (genotype A2dB1). Poultry Science. 2024. DOI: https://doi.org/10.1016/j.psj.2024.103552

[2] Zhu K, Wu Q, Leng M, Wang Z, Lin W. Phylogenetic analysis of vp2 gene of the infectious bursal disease virus in South China during 2023. Frontiers in Veterinary Science. 2025. DOI: https://doi.org/10.3389/fvets.2025.1575407

[3] Fan L, Wu T, Wang Y, Hussain A, Jiang N, Gao L, et al.. Novel variants of infectious bursal disease virus can severely damage the bursa of fabricius of immunized chickens.. Veterinary Microbiology. 2020. DOI: https://doi.org/10.1016/j.vetmic.2019.108507

[4] Abotaleb M, Soliman R, Shaheen H, Yousef G, Fouad E, Zaid RA, et al.. Molecular Characterization of Infectious Bursal Disease Virus Circulating Among Broiler Chickens Flocks in Qalubia and Mounofia Governorates, Egypt. Alexandria Journal of Veterinary Sciences. 2026. DOI: https://doi.org/10.5455/ajvs.303422

[5] Egana-Labrin S, Brodrick A, Khalid Z, Kehlbeck D, Liu M, Dong J, et al.. Molecular characterization of infectious bursal disease virus (IBDV) strains of genogroup A2B1 circulating in Delaware, Maryland, and Virginia from 2018 to 2023. Microbiology spectrum. 2026. DOI: https://doi.org/10.1128/spectrum.02976-25

[6] Zhang W, Wang X, Gao Y, Qi X. The Over-40-Years-Epidemic of Infectious Bursal Disease Virus in China. Viruses. 2022. DOI: https://doi.org/10.3390/v14102253

[7] Huang Y, Shu G, Huang C, Han J, Li J, Chen H, et al.. Characterization and pathogenicity of a novel variant infectious bursal disease virus in China. Frontiers in Microbiology. 2023. DOI: https://doi.org/10.3389/fmicb.2022.1039259

[8] Pikuła A, Lisowska A, Domańska-Blicharz K. Epidemiology of Infectious Bursal Disease Virus in Poland during 2016–2022. Viruses. 2023. DOI: https://doi.org/10.3390/v15020289

[9] Bo Z, Wang S, Xu K, Zhang C, Guo M, Cao Y, et al.. Isolation and genomic characteristics of the novel variant infectious bursal disease virus in China. Frontiers in Veterinary Science. 2023. DOI: https://doi.org/10.3389/fvets.2023.1314903

[10] Fan L, Wu T, Hussain A, Gao Y, Zeng X, Wang Y, et al.. Novel variant strains of infectious bursal disease virus isolated in China.. Veterinary Microbiology. 2019. DOI: https://doi.org/10.1016/j.vetmic.2019.01.023

[11] Mató T, Medveczki A, Kiss I. Research Note: “Hidden” infectious bursal disease virus infections in Central Europe. Poultry Science. 2022. DOI: https://doi.org/10.1016/j.psj.2022.101958

[12] Lian J, Wang Z, Xu Z, Pang Y, Leng M, Tang S, et al.. Pathogenicity and molecular characterization of infectious bursal disease virus in China. Poultry Science. 2021. DOI: https://doi.org/10.1016/j.psj.2021.101502

[13] Xu A, Pei Y, Zhang K, Xue J, Ruan S, Zhang G. Phylogenetic analyses and pathogenicity of a variant infectious bursal disease virus strain isolated in China.. Virus Research. 2019. DOI: https://doi.org/10.1016/j.virusres.2019.197833

[14] Jackwood D, Schat K, Michel L, Wit SJd. A proposed nomenclature for infectious bursal disease virus isolates. Avian Pathology. 2018. DOI: https://doi.org/10.1080/03079457.2018.1506092

[15] Yılmaz A, Turan N, Bayraktar E, Gürel A, Cizmecigil UY, Aydin O, et al.. Phylogeny and evolution of infectious bursal disease virus circulating in Turkish broiler flocks. Poultry Science. 2019. DOI: https://doi.org/10.3382/ps/pey551

[16] Bayraktar E, Aydin O, Tali HE, Ozkan I, Umar S, Tali HB, et al.. Predominance of reassortant infectious bursal disease viruses in Turkish poultry flocks. Poultry Science. 2025. DOI: https://doi.org/10.1016/j.psj.2025.105974

[17] Rautenschlein S, Schat K, Saif YM. The History of Infectious Bursal Disease: The Second Period Between 1977 and 2005.. Avian diseases. 2025. DOI: https://doi.org/10.1637/aviandiseases-d-24-00095

[18] Kasanga C, Yamaguchi T, Munang'andu H, Ohya K, Fukushi H. Molecular epidemiology of infectious bursal disease virus in Zambia.. Journal of the South African Veterinary Association. 2013. DOI: https://doi.org/10.4102/jsava.v84i1.908

[19] Giambrone J, Dormitorio T, Brown T, Takeshita K. Monitoring the Immune Status of Broiler Breeders Against Infectious Bursal Disease Virus Using Progeny Challenge and Serologic Data. The Journal of Applied Poultry Research. 1999. DOI: https://doi.org/10.1093/JAPR/8.3.362

[20] El-Fetouh MSA, Abdallah F. Genetic characterization of Infectious Bursal Disease Viruses isolated from the vaccinated broiler chicken flocks in Egypt during 2015-2016.. Polish journal of veterinary sciences. 2018. DOI: https://doi.org/10.24425/124293

[21] Yu H, Wang G, Zhang W, Wu Z, Niu X, Huang M, et al.. Epidemiological characteristics of infectious bursal disease virus (IBDV) in China from 2023 to 2024: Mutated very virulent IBDV (mvvIBDV) is associated with atypical IBD. Poultry Science. 2025. DOI: https://doi.org/10.1016/j.psj.2025.105195

[22] Xiong H, Wu J, Xie Q, Li T, Wan Z, Qin A, et al.. Q221K mutation in VP2 drives antigenic shift of infectious bursal disease virus. Frontiers in Immunology. 2025. DOI: https://doi.org/10.3389/fimmu.2025.1600371

[23] Wang W, Wu J, Jiang N, Liang Q, Liu R, Fu Q, et al.. Advances in Infectious Bursal Disease Virus Vaccines, A Review. Microorganisms. 2025. DOI: https://doi.org/10.3390/microorganisms13122801

[24] Hair-Bejo M, Mazlan M, Hao H, Be HT, Sohaimi N, Ugwu CC. Pathogenicity, Humoral Immune Response, and Organ Tropism of Novel Variant Infectious Bursal Disease Virus in Commercial Broiler Chickens.. Avian diseases. 2025. DOI: https://doi.org/10.1637/aviandiseases-d-24-00104

[25] Cádiz L, Guzmán M, Rivera P, Navarrete F, Torres P, Hidalgo H. First Isolation, Molecular Identification, and Phylogenetic Characterization of A3B5 Very Virulent Infectious Bursal Disease Virus in Pullets in Chile. Microbiology Research. 2025. DOI: https://doi.org/10.3390/microbiolres16020031

[26] Dastjerdi P, Bejo M, Rahaman NYA, Raji A, Soontravanich R, Tai SR, et al.. Characterization of immunosuppression of genotype A2dB1 variant infectious bursal disease virus isolated in Malaysia using specific pathogen-free and commercial broiler chickens. Veterinary World. 2025. DOI: https://doi.org/10.14202/vetworld.2025.799-807

[27] Salaheldin AH, El-Hamid HSA, Ellakany HF, Mohamed M, Elbestawy A. Isolation, Molecular, and Histopathological Patterns of a Novel Variant of Infectious Bursal Disease Virus in Chicken Flocks in Egypt. Veterinary Sciences. 2024. DOI: https://doi.org/10.3390/vetsci11020098

[28] Takahashi M, Oguro S, Kato A, Ito S, Tsutsumi N. Novel Antigenic Variant Infectious Bursal Disease Virus Outbreaks in Japan from 2014 to 2023 and Characterization of an Isolate from Chicken. Pathogens. 2024. DOI: https://doi.org/10.3390/pathogens13121141

[29] Tomás G, Techera C, Marandino A, Olivera V, Williman J, Panzera Y, et al.. Genomic characterization of infectious bursal disease virus in Argentina provides evidence of the recent transcontinental spread of Chinese genotype A2dB1b. Avian Pathology. 2024. DOI: https://doi.org/10.1080/03079457.2024.2355918

[30] Liang Z, Leng M, Lian J, Chen Y, Wu Q, Chen F, et al.. Novel variant infectious bursal disease virus diminishes FAdV-4 vaccination and enhances pathogenicity of FAdV-4.. Veterinary Microbiology. 2024. DOI: https://doi.org/10.1016/j.vetmic.2024.110053

[31] Wang G, Jiang N, Yu H, Niu X, Huang M, Zhang Y, et al.. Loop PDE of viral capsid protein is involved in immune escape of the emerging novel variant infectious bursal disease virus.. Veterinary Microbiology. 2024. DOI: https://doi.org/10.1016/j.vetmic.2024.110094

[32] Wang W, Huang Y, Zhang Y, Qiao Y, Shi J, Huang J, et al.. The complete protections induced by the oil emulsion vaccines of the novel variant infectious bursal disease viruses against the homologous challenges indicating the important roles of both VP2 and VP1 in the antigenicity and pathogenicity of the virus. Frontiers in Veterinary Science. 2024. DOI: https://doi.org/10.3389/fvets.2024.1466099

[33] Poletto F, Alam S, Cherfane A, Franzo G, Tucciarone C, Cecchinato M, et al.. Rapid Spread of Novel Infectious Bursal Disease Virus Variant (Genotype A2dB1b) in the Near East and Persian Gulf Regions: Molecular Surveillance and Phylodynamic Reconstruction. Transboundary and Emerging Diseases. 2026. DOI: https://doi.org/10.1155/tbed/7950151

[34] Hair-Bejo M, Mazlan M, Be TH, Han C, Sohaimi N, Ugwu CC. Pathogenicity, immunogenicity, and multi-organ tissue tropism of a novel variant infectious bursal disease virus in specific pathogen-free chickens. Veterinary World. 2026. DOI: https://doi.org/10.14202/vetworld.2026.591-603

[35] Ito S, Takahashi M, Shibuya K, Kato A, Tsutsumi N, Sugiura K. Pathogenicity of the novel antigenic variant infectious bursal disease virus B2977CE2C3 isolated in Japan: Histological analysis of experimentally infected chickens.. Veterinary Pathology-Supplement. 2026. DOI: https://doi.org/10.1177/03009858251415335

[36] Li K, Niu X, Jiang N, Zhang W, Wang G, Li K, et al.. Comparative Pathogenicity of Three Strains of Infectious Bursal Disease Virus Closely Related to Poultry Industry. Viruses. 2023. DOI: https://doi.org/10.3390/v15061257

[37] Legnardi M, Poletto F, Talaat S, Selim KM, Moawad MK, Franzo G, et al.. First Detection and Molecular Characterization of Novel Variant Infectious Bursal Disease Virus (Genotype A2dB1b) in Egypt. Viruses. 2023. DOI: https://doi.org/10.3390/v15122388

[38] Tian C, Ren Z, Chang S, Cui W, Zhao P, Wang Y. Effect of infectious bursal disease virus infection on the expression of immune checkpoint molecules in SPF chickens.. Veterinary Immunology and Immunopathology. 2025. DOI: https://doi.org/10.1016/j.vetimm.2025.110933

[39] Xiong H, Wu J, Wang S, Zhang J, Zhang W, Wan Z, et al.. Comprehensive transcriptome profiling of the chicken bursa infected with the novel variant infectious bursal disease virus. Poultry Science. 2025. DOI: https://doi.org/10.1016/j.psj.2025.106260

[40] Ibrahim M, Ayman D, Arafa W, Abdelmagid M, El-sanousi A, Shaheen M. Comparative pathogenicity of very virulent and novel variant infectious bursal disease virus Egyptian strains in chickens. Virology Journal. 2026. DOI: https://doi.org/10.1186/s12985-026-03111-7

[41] Hu X, Chen Z, Wu X, Ding Z, Huang Y, Fu Q, et al.. Phosphorylation of VP1 Mediated by CDK1-Cyclin B1 Facilitates Infectious Bursal Disease Virus Replication. Journal of Virology. 2023. DOI: https://doi.org/10.1128/jvi.01941-22

[42] Hu X, Chen Z, Wu X, Fu Q, Chen Z, Huang Y, et al.. PRMT5 Facilitates Infectious Bursal Disease Virus Replication through Arginine Methylation of VP1. Journal of Virology. 2023. DOI: https://doi.org/10.1128/jvi.01637-22

[43] Asfor A, Reddy VR, Nazki S, Urbaniec J, Brodrick A, Broadbent A. Modeling Infectious Bursal Disease Virus (IBDV) Antigenic Drift In Vitro. Viruses. 2022. DOI: https://doi.org/10.3390/v15010130

[44] Cubas-Gaona LL, Courtillon C, Briand F, Cotta H, Bougeard S, Hirchaud E, et al.. High antigenic diversity of serotype 1 infectious bursal disease virus revealed by antigenic cartography. Virus Research. 2022. DOI: https://doi.org/10.1016/j.virusres.2022.198999

[45] Zhang J, Park J, Kim S, Choi Y, Cha S, Jang H, et al.. Development of a Highly Efficient CRISPR/Cas9-Mediated Herpesvirus of Turkey-Based Vaccine against Novel Variant Infectious Bursal Disease Virus. Vaccines. 2024. DOI: https://doi.org/10.3390/vaccines12030226

[46] Aliyu HB, Hamisu TM, Hair-Bejo M, Omar A, Ideris A. Immuno-protective effect of commercial IBD vaccines against emerging novel variant infectious bursal disease virus in specific-pathogen-free chickens. Journal of Veterinary Sciences. 2024. DOI: https://doi.org/10.4142/jvs.23297

[47] Elkohely K, Al-Ebshahy E, Eleraky N, AboElkhair M. Molecular Characterization of Infectious Bursal Disease Virus in Vaccinated Chicken Flocks in Egypt During 2025. Alexandria Journal of Veterinary Sciences. 2026. DOI: https://doi.org/10.5455/ajvs.294685

[48] Fraga APd, Gräf T, Coltro VP, Ikuta N, Fonseca A, Majó N, et al.. Phylodynamic analyses of Brazilian antigenic variants of infectious bursal disease virus.. Infection, Genetics and Evolution. 2019. DOI: https://doi.org/10.1016/j.meegid.2019.04.020

[49] Alkhalefa N, El-Abasy M, Kasem S, El-Naga EA. Molecular characterisation of infectious bursal disease virus (IBDV) isolated from commercial broiler chickens in Nile Delta. Bulgarian Journal of Veterinary Medicine. 2019. DOI: https://doi.org/10.15547/bjvm.2133

[50] Zhang Y, Wu Z, Yu H, Wang G, Liu R, Ling D, et al.. Vaccination with Lipid Nanoparticle-Delivered VP2-DNA Elicits Immune Protection in Chickens Against Novel Variant Infectious Bursal Disease Virus (nVarIBDV).. Vaccines. 2026. DOI: https://doi.org/10.3390/vaccines14020113

[51] Cazaban C, Rmw R, Jjd W, Palya, Gardin Y. Field Assessment of an Immune-Complex Infectious Bursal Disease Vaccine in Chicks Born to Non-Hyperimmunized Broiler Breeders. Journal of Veterinary Science and Animal Husbandry. 2018. DOI: https://doi.org/10.15744/2348-9790.6.302

[52] Wang W, Zhang Y, Zuo W, Qiao Y, Shi J, Huang J, et al.. Rapid identification, pathotyping and quantification of infectious bursal disease virus by high-resolution melting curve quantitative reverse transcription PCR analysis: An innovative technology well-suited for real-time large-scale epidemiological surveillance. Poultry Science. 2024. DOI: https://doi.org/10.1016/j.psj.2024.104440

[53] Qiao Q, Song M, Song C, Zhang Y, Wang X, Huang Q, et al.. Single-Dose Vaccination of Recombinant Chimeric Newcastle Disease Virus (NDV) LaSota Vaccine Strain Expressing Infectious Bursal Disease Virus (IBDV) VP2 Gene Provides Full Protection against Genotype VII NDV and IBDV Challenge. Vaccines. 2021. DOI: https://doi.org/10.3390/vaccines9121483

[54] Fan X, Li B, Zhu L, Shen Y, Zhou H, Ding G, et al.. Development and evaluation of immunogenicity and protective efficacy of two recombinant attenuated newcastle disease viruses expressing the VP2 protein of infectious bursal disease virus. Poultry Science. 2025. DOI: https://doi.org/10.1016/j.psj.2025.105253

[55] Hair-Bejo M, Gauthaman L, Mazlan M, Sohaimi N, Ugwu CC. Efficacy and Safety of an Inactivated Novel Variant Infectious Bursal Disease Virus in Broiler Chickens. The Journal of World's Poultry Research. 2024. DOI: https://doi.org/10.36380/jwpr.2024.1

[56] Zhu K, Chang S, Zhao P, Che C, Ren Z, Cui W, et al.. Inhibitory effect of transfer factor on infection with the novel variant strain of infectious bursal disease virus in chickens. Poultry Science. 2026. DOI: https://doi.org/10.1016/j.psj.2026.106785

[57] Asif TA, Ji P, Qiao X, Yang Q, Jiang D, Zhang G. Nano-adjuvants enhance the immunogenicity and safety of infectious bursal disease virus vaccines: a comprehensive review. Frontiers in Immunology. 2026. DOI: https://doi.org/10.3389/fimmu.2026.1805229

[58] Gul I, Hassan A, Muneeb J, Akram T, Haq E, Shah R, et al.. A multiepitope vaccine candidate against infectious bursal disease virus using immunoinformatics-based reverse vaccinology approach. Frontiers in Veterinary Science. 2023. DOI: https://doi.org/10.3389/fvets.2022.1116400